Abstract
Schizophrenia is a highly heritable brain disorder with a typical symptom onset in early adulthood. The two-hit hypothesis posits that schizophrenia results from deviant early neurodevelopment, predisposing an individual, followed by a disruption of later brain maturational processes that trigger the onset of symptoms. Here, we investigate how the timing of expression of 345 putative schizophrenia risk genes may aid in understanding the interplay of neurobiological processes in the pathophysiology of schizophrenia. Clustering of brain transcriptomic data across the lifespan revealed a set of 183 genes that was significantly upregulated prenatally and downregulated postnatally and 162 genes that showed the opposite pattern. The prenatally upregulated set of genes was functionally annotated to fundamental cell cycle processes, while the postnatally upregulated set was associated with the immune system and neuronal communication. We subsequently calculated two set-specific polygenic risk scores for 743 individuals with schizophrenia and 743 sex- and age-matched healthy controls. We found an interaction between the two scores; higher prenatal polygenic risk was only significantly associated with schizophrenia diagnosis and severity, at higher levels of postnatal polygenic risk. We therefore provide genetics-based evidence in favor of the two-hit hypothesis, supporting that schizophrenia may be shaped by disruptions of separable biological processes acting at distinct phases of neurodevelopment.
Competing Interest Statement
Dr. Andreassen has received speaker honorarium from Lundbeck, and is a consultant to HealthLytix. The other authors declare no competing financial interests.
Funding Statement
The authors were funded by the Research Council of Norway (276082, 323961, 213837, 223273, 204966/F20, 229129, 249795/F20, 225989, 248778, 249795, 298646, 300767), the South-Eastern Norway Regional Health Authority (2013-123, 2014-097, 2015-073, 2016-064, 2017-004, 2019-101, 2019-107, 2020-086), Stiftelsen Kristian Gerhard Jebsen (SKGJ-Med-008), The European Research Council (ERC) under the European Union Horizon 2020 research and innovation programme (ERC Starting Grant, Grant agreement No. 802998).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Oslo Regional Committee for Medical Research Ethics and the Norwegian Data Inspectorate gave ethical approval for this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data incorporated in this work were gathered from public resources. The code is available via https://github.com/norment/open-science [published upon acceptance]. Correspondence and requests for materials should be addressed to d.v.d.meer{at}medisin.uio.no